8-11 November 2018 Amsterdam
P-005 | Follow-up and long-term comparison of the 8 and 12 cylinder scheme in prostate biopsy | Pau Sarrió-Sanz | Received |
P-006 | Improving Standard Trans-Rectal Prostate Biopsy Results Using High Resolution Micro-Ultrasound Real-Time Targeting for Suspicious Areas | Robert Sandler | Received |
P-007 | Initial Clinical Experience with 29 MHz Micro-Ultrasound for Real-Time Targeted Prostate Biopsies | Robert Sandler | Received |
P-008 | Where Do Micro-Ultrasound and MRI Find Prostate Cancer? A Target Localization Study | Robert Sandler | Received |
P-009 | Learning curve and distribution of PI-RADS score in a population based series of Norwegian men examined with a mpMRI detection protocol | Martin Landquist | Received |
P-010 | Assessment of ADC measurement using mpMRI in patients with low-risk prostate cancer (PCa) after radical prostatectomy (RP) | Dmitry Goncharuk | Received |
P-011 | Does high PIRADS V2 Score on a pre biopsies Multiparametric MRI scan suggest high-Gleason score prostate cancer? | Israr Khan | Received |
P-013 | Prostate cancer incidence related to favourable free/total PSA ratio. | Virginia del Rosario Rodriguez | Received |
P-020 | Validation and face to face comparison of three preoperative nomograms for prediction of lymph node invasion before radical prostatectomy | Angeles Sanchis-Bonet | Received |
P-021 | Should residents perform Laparoscopic Radical Prostatectomy? Datebase analysis | rodriguez lopez sabela | Received |
P-023 | Increasing Time from Diagnosis to Radical Prostatectomy (RP-interval) is Not Associated with Adverse Oncological Outcomes: Implications for cancer patient pathways (CPPs) | Kirsti Aas | Received |
P-040 | Correlation between the location of the index tumour and the location of positive lymph nodes in high-risk prostate cancer. A monocentric positive lymph node mapping study | Brecht Jacobs | Received |
P-041 | Effect of PectaSol-C modified citrus pectin (P-MCP) treatment (tx) on PSA Dynamics in non- metastatic Biochemically Relapsed Prostate Cancer (BRPC) patients (pts): Results of a prospective Phase II Study | Charles Hartmann | Received |
P-048 | Post-docetaxel survival in metastatic castration-resistant prostate cancer (mCRPC) is improving in the Netherlands | Malou Kuppen | Received |
P-049 | Efficacy of Abiraterone acetate plus Prednisone and Enzalutamide sequences in men with metastatic castration-resistant prostate cancer: Systematic review and meta-analysis | Paola Moreno | Received |
P-051 | Potential prognostic factors for metastatic castration resistant prostate cancer with Abiraterone Acetate | Cecília Maria de Melo Alvim Moreira | Received |
P-053 | Incidence of urological complications in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first line abiraterone and enzalutamide | JAVIER LORCA | Received |
P-055 | Enzalutamide in metastatic castration resistant prostate cancer, a single center experience | Rita Paiva | Received |
P-056 | A single-center experience with abiraterone acetate in metastatic castration resistant prostate cancer | Ana Afonso | Received |
P-058 | Survival impact of the management of medical and urological complications during treatment with 1st line abiraterone (A) or enzalutamide (E) in patients with metastatic castration-resistant prostate cancer (mCRPC) | Juan Jose Serrano Domingo | Received |
P-061 | Prognostic impact of end of radiotherapy PSA (EORT-PSA) on long-term outcomes in patients with N1 prostate cancer (PC) | Trude Wedde | Received |
P-063 | Prostate volume reduction in patients treated with Abiraterone and Enzalutamide: The forgotten outcome in Clinical trials | Sara Alvarez Rodríguez | Received |
P-064 | Exercise prescription dose for castration resistant prostate cancer patients: A phase I prescription dose escalation trial | Renée Bultijnck | Received |
P-067 | Risk of postoperative upstaging or upgrading among men with low-risk familial prostate cancer: PCBaSe Sweden | Fredrik Jansson | Received |
P-072 | Enzalutamide with or without prior anti-androgen treatment for castration resistant prostate cancer (CRPC): Results from the Dutch CAPRI registry | Malou Kuppen | Received |
P-082 | Multicenter registry of CRPC patients: Clinical characteristics and natural history of the disease | Victor Jose Valencia Guadalajara | Received |
P-087 | Isolation and characterization of urine exosomes for using as diagnostic biomarkers in Prostate Cancer | Angeles Sanchis-Bonet | Received |
P-095 | MRI for assessment of inferior vena cava wall invasion by renal cell carcinoma with vena cava thrombi | Tim van Oostenbrugge | Received |
P-100 | Dynamics of markers of acute kidney injury in renal cell carcinoma patients after laparoscopic partial nephrectomy under warm ischemia of the kidney | Sergey Dimitriadi | Received |
P-115 | Overall and progression free survival time in mRCC patients Clinicopathological risk group analysis | Joanna Huszno | Received |
P-116 | A lower psoas muscle volume correlates with a higher recurrence rate in male clear cell renal cell carcinoma patients | Go Noguchi | Received |
P-123 | Increased activation of mammalian target of rapamycin pathway in renal cell carcinoma arising in native kidneys of dialyzed patients | Ryuichi Mizuno | Received |
P-135 | Does neoadjuvant chemotherapy affect postoperative complication rates in elderly patients treated with radical cystectomy for bladder cancer? | Ryuichi Mizuno | Received |
P-136 | Could adjuvant chemotherapy have additional therapeutic benefit in muscle invasive bladder cancer patients treated with radical cystectomy and neoadjuvant chemotherapy? | Ryuichi Mizuno | Received |
P-149 | Monopolar transurethral resection of bladder tumors preformed by a urology resident: Is it safe for the patient? | Francisco José Damas Arroyo | Received |
P-152 | Predictors for development 30-day complications after radical cystectomy (RC) | Denis Ledyaev | Received |
P-153 | Pre-treatment lymphocytopenia predicts poor prognosis for patients with metastatic urothelial carcinoma treated with platinum-based first-line chemotherapy | Susumu Umemoto | Received |
P-163 | Expression of the microRNAs miR-100, miR-138 y miR-let-7c in non-muscle invasive bladder cancer: clinicopathological significance and prognostic value | ALVARO SANCHEZ GONZALEZ | Received |
P-165 | The role of frozen section examination (FSE) during inguinal exploration in 1052 patients with inconclusive testicular lesions | Christian Fankhauser | Received |
P-170 | Clinical analysis of extragonadal germ cell tumors in our hospital | Sohgo Tsutsumi | Received |
8-11 November 2018 Amsterdam
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|